Iranian Journal of Parasitology 2017. 12(3):441-445.

Designing a DNA Vaccine-based Leishmania major Polytope (Preliminary Report)


Background: Leishmaniasis is a neglected disease affecting millions of people worldwide. The treatment of the disease is hampered due to high cost, toxicity and the crisis of drug resistance. Polytope approaches of genetic immunization could be a strategy for prevention of infectious diseases. Furthermore, the identification of Leishmania genome sequence and the application of bioinformatics assist us to devise an effective vaccine’s candidate.

Methods: A linear sequence from predicted epitopes of GP63, LACK and CPC antigens was designed and was optimized using online available algorithms. The synthesized sequence (LAKJB93) was ligated to pEGFP-N1 plasmid.

Results: The 264bp sequence was cloned at N terminal of GFP into pEGFP_N1 expression vector and transfect into CHO cell line. Construct was efficient expressed in CHO cells.

Conclusion: The protein of LAKJB93 cosnstruct was expressed in CHO cells successfully.


DNA vaccine, Polytope, Leishmania major

Full Text:



Larry S Roberts, Gerald D. Schmidt. Foundations of Parasitology. 9th ed. McGraw-Hill Higher Education. 2009.

Organization WH. Control of the leishmaniasis: Report of a meeting of the WHO expert committee on the control of leishmaniases, Geneva, 22-26 March 2010. Geneva, switzerland: Who; 2010.

Handman E. Leishmaniasis: Current status of vaccine development. Clin Microbiol Rev. 2001; 14(2):229-43.

Khamesipour A, Rafati S, Davoudi N et al. Leishmaniasis vaccine candidates for development: A global overview. Indian J Med Res. 2006; 123(3):423-38.

Nadim A, Javadian E, Mohebali M. The experience of leishmanization in the islamic republic of iran. East Mediterr Health J. 1997;3(2):284-289.

Mutiso JM, Macharia JC, Kiio MN et al. Development of Leishmania vaccines: Predicting the future from past and present experience. J Biomed Res. 2013; 27(2):85-102.

Raman VS, Duthie MS, Fox CB et al. Adjuvants for Leishmania vaccines: From models to clinical application. Front Immunol. 2012;3:144.

Kedzierski L. Leishmaniasis. Hum Vaccin. 2011; 7(11):1204-14.

De Groot AS, McMurry J, Marcon L et al. Developing an epitope-driven tuberculosis (tb) vaccine. Vaccine. 2005; 23(17-18):2121-31.

Elfaki ME, Khalil EA, De Groot AS et al. Immunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccines. Hum Vaccin Immunother. 2012; 8(12):1769-74.

Gurunathan S, Sacks DL, Brown DR et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med. 1997; 186(7):1137-47.

Khoshgoo N, Zahedifard F, Azizi H et al.Cysteine proteinase type III is protective against Leishmania infantum infection in balb/c mice and highly antigenic in visceral leishmaniasis individuals. Vaccine. 2008; 26(46):5822-9.

Jain K, Jain NK. Vaccines for visceral leishmaniasis: A review. J Immunol Methods.. 2015; 422:1-12.

Basu R, Bhaumik S, Basu JM et al. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and-resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: Evidence for mixed th1-and th2-like responses in visceral leishmaniasis. J Immunol. 2005; 174(11):7160-71.

Basu R, Roy S, Walden P. Hla class i—restricted t cell epitopes of the kinetoplastid membrane protein—11 presented by Leishmania donovani—infected human macrophages. J Infect Dis. 2007; 195(9):1373-80.

Jain K, Jain NK. Novel therapeutic strategies for treatment of visceral leishmaniasis. Drug Discov Today. 2013; 18(23-24):1272-81.

Choudhury R, Das P, De T et al. 115KDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated mmp-9 activity. Immunobiology. 2013; 218(1):114-26.

Ponte CB, Alves EA, Sampaio RN et al. Miltefosine enhances phagocytosis but decreases nitric oxide production by peritoneal macrophages of C57BL/6 mice. Int Immunopharmacol. 2012; 13(1):114-9.

Kelly BL, Stetson DB, Locksley RM. Leishmania major lack antigen is required for efficient vertebrate parasitization. J Exp Med. 2003; 198(11):1689-98.

Gómez-Arreaza A, Acosta H, Barros-Álvarez X et al. Leishmania mexicana: Lack (Leishmania homolog of receptors for activated c-kinase) is a plasminogen binding protein. Exp Parasitol. 2011; 127(4):752-61.

Tapia E, Pérez-Jiménez E, López-Fuertes L et al. The combination of DNA vectors expressing IL-12+ IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/lack and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK. Microbes Infect. 2003; 5(2):73-84.

Abdelhak S, Louzir H, Timm J et al. Recombinant bcg expressing the Leishmania surface antigen gp63 induces protective immunity against Leishmania major infection in balb/c mice. Microbiology. 1995; 141 ( Pt 7):1585-92.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.